Technical Analysis for MRSN - Mersana Therapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
MRSN closed up 1.37 percent on Monday, December 10, 2018, on approximately normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
|See historical MRSN trend table...|
|Date||Alert Name||Type||% Chg|
|Dec 10||New 52 Week Low||Weakness||0.00%|
|Dec 10||Wide Bands||Range Expansion||0.00%|
|Dec 10||Oversold Stochastic||Weakness||0.00%|
|Dec 7||New 52 Week Closing Low||Bearish||1.37%|
|Dec 7||1,2,3 Retracement Bearish||Bearish Swing Setup||1.37%|
|Dec 7||180 Bearish Setup||Bearish Swing Setup||1.37%|
|Dec 7||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||1.37%|
|Dec 7||Outside Day||Range Expansion||1.37%|
|Dec 7||Wide Bands||Range Expansion||1.37%|
|Dec 7||Oversold Stochastic||Weakness||1.37%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Mersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug's chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies. XMT-1522 is based on its Dolaflexin platform and has over 15 auristatin molecules per antibody. XMT-1522 is in Phase I clinical trial for various indications of cancers. XMT-1536 is in pre-clinical development.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more MRSN news...
|52 Week High||23.96|
|52 Week Low||4.96|
|200-Day Moving Average||13.4772|
|50-Day Moving Average||6.9484|
|20-Day Moving Average||5.6415|
|10-Day Moving Average||5.395|
|Average True Range||0.5524|
|Chandelier Exit (Long, 3 ATRs )||5.2628|
|Chandelier Exit (Short, 3 ATRs )||6.6172|
|Upper Bollinger Band||6.5336|
|Lower Bollinger Band||4.7494|
|Percent B (%b)||0.24|
|MACD Signal Line||-0.6122|
|Market Cap||117.65 Million|
|Num Shares||22.7 Million|
|Price-to-Earnings (P/E) Ratio||-0.32|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||5.68|
|Resistance 3 (R3)||5.66||5.47||5.59|
|Resistance 2 (R2)||5.47||5.35||5.48||5.56|
|Resistance 1 (R1)||5.33||5.27||5.40||5.35||5.54|
|Support 1 (S1)||5.00||5.02||5.07||5.02||4.82|
|Support 2 (S2)||4.81||4.94||4.82||4.80|
|Support 3 (S3)||4.67||4.81||4.77|
|Support 4 (S4)||4.69|